Covid-19 News

  • This isnt 911, the evidence is in code -- forget about a coverup -- they will have police all thought and enforce a digital fascist state where they delete much of what any intelligent questioning scientist says. If anyone thinks that they are part of a Death Cult who is against vaccines and total liars, right?

    You totally overestimate the intelligence of these people that are in command. Greed and Drugs of any kind have shrunken their mind to be of "cricket brain" equivalence. They possibly never saw a real upraise. This soon will happen here in Europe if the fake lock down for helping big Pharma (selling outdated vaccines) will last some more weeks. Netherlands had a good start already.

  • Doing some worst case planning and purchased the only Ivermectin available to me in the horse version, 6.08g dose @ 1.87% Apple Flavor. Enough for a 1200Lb horse for normal worming routine. Looked through prior posts and could not determine the consensus dosage and protocol/ Kg to administer assuming the individual has recently contracted Covid? Any input would be appreciated.


    81Q-TkZEOxL._AC_SL1500_.jpg

  • UK Prime minister urged, ‘Look to Andalusia’s vitamin D use in tackling COVID-19’


    https://www.nutraingredients.c…-s-vit-D-use-for-COVID-19


    UK Prime Minister Boris Johnson has been urged to follow the example of Andalusia and distribute vitamin D supplements to populations most at risk of contracting COVID-19.


    In last week’s Prime Minister Questions (PMQs), Conservative backbencher David Davis MP pointed to the Spanish region’s distribution of calcifediol, a vitamin D supplement, to care home residents in November.Latest figures from Andalusia highlight a drop in deaths per million from COVID-19 from 187 in November to just 11 at the start of January - an 82% drop.


    “After giving out activated vitamin D to care home residents and some GP patients that death rate almost halved whilst ours was doubled,” Davis said.

  • UK Prime Minister Boris Johnson has been urged to follow the example of Andalusia and distribute vitamin D supplements to populations most at risk of contracting COVID-19.

    Look at https://vdmeta.com/


    Even for treatement V-D3 works pretty well! With 40'000 to 50'000 IU's dosage it brings up to 90% death reduction.


    I just bought a bottle of 5000IU capsules to have one more weapon ready for complex cases.

  • In the Geneva location they now have 40% UK virus cases. The statistics did show a short increase in cases about 2 weeks ago:

    https://github.com/openZH/covi…ahlen_Kanton_GE_total.csv


    May be JulianBianchi knows more details!


    But now it goes down as before. Also no excess deaths as claimed by UK. But the number of cases are small. So it looks like B1.171 just brings a small additional bump!

    But if you add 484 similar to 501.V2 or B.1.351 the mess seems to start again. Now 90 cases confirmed in UK already.


    It's time to teach the people how to treat CoV-19 to make this a mild disease!

  • Immunity sometimes fail? Really? Define sometimes Jed.

    With the Covid 19 “vaccine” today, it fails at immunization 100% of the time, it does NOT, never has, and was never said to make anyone immune, ever. Even in “Jed land” that simply cannot qualify as a vaccine.

    So, if it clearly is NOT a vaccine, what exactly is it? A glorified flu shot?

    Hmmmm...


    • People may need to get vaccinated against Covid-19 annually, just like seasonal flu shots, over the next several years, Johnson & Johnson CEO Alex Gorsky told CNBC on Tuesday.
  • Hmmmm...


    • People may need to get vaccinated against Covid-19 annually, just like seasonal flu shots, over the next several years, Johnson & Johnson CEO Alex Gorsky told CNBC on Tuesday.

    Of course, it is called original antigenic sin. By avoiding a natural infection, you are not getting the benefits of a potentially powerful life-long T-cell response.

  • Of course, it is called original antigenic sin. By avoiding a natural infection, you are not getting the benefits of a potentially powerful life-long T-cell response.

    This is nonsense. There is no difference between the antibodies produced by the virus and those produced by the vaccine. There is no way to tell them apart.

  • No need to respond to the above ^ message. OAS is real.


    But more logic: IFR of an 80 year old outside a nursing home is 50% less compared to in a nursing home. Improving nursing homes would actually be a better investment for saving / extending lives than shutting down society, vaccinating every human on earth, and killing lives and businesses leading to misery for years.

  • It is not surprising to find all variants here in Geneva given that it is so international. I work in the same area as most international organizations (UN, WHO, WTO, etc...) and take the same tram every day from the Geneva main train station as the employees of these organizations. I know that I was exposed to the so-called UK variant (I hate this wording...) at least once but hopefully without any symptoms. I still do not have specific anti-SARS-COV-2 antibodies despite that I have been exposed to the virus at several occasions since March last year. My Vit D blood levels are fine, around 45 ng/ml, I test myself regularly for Vit D together with Zn, Se, Mg, Omega-3s, Vit B1, etc... (our lab propose a COVID-19 Immunity home test on top of blood and saliva SARS-COV-2 antigen tests, way better than RT-PCR). I guess that my T-cells are working well ;)

  • Coronavirus vaccination may be cause of rare blood disorder in at least 36 people: report

    An estimated 50,000 people in the U.S. are currently living with and successfully managing immune thrombocytopenia, according to the Platelet Disorder Support Association


    https://www.foxnews.com/us/cor…east-36-people-report.amp


    According to The New York Times, the cases were reported to VAERS, the government’s Vaccine Adverse Event Reporting System, as of the end of January. However, the system relies on individuals to send in reports of their experiences to the CDC and FDA, and does not indicate whether vaccines actually caused the problems.


    Over 43 million COVID-19 vaccine doses have been administered in the United States, with over 32 million Americans receiving at least one dose, according to the latest data Tuesday from the Centers for Disease Control and Prevention. No cases of thrombocytopenia were reported during the trials of either Moderna's or Pfizer's vaccines.


    A Pfizer spokesperson told FOX News it is "aware of cases of thrombocytopenia in recipients of our COVID-19 vaccine" and takes reports of adverse events "very seriously."

    We are collecting relevant information to share with the FDA. However, at this time, we have not been able to establish a causal association with our vaccine," the spokesperson added. "To date, millions of people have been vaccinated and we are closely monitoring all adverse events in individuals receiving our vaccine. Serious adverse events, including deaths that are unrelated to the vaccine, are unfortunately likely to occur at a similar rate as they would in the general population."


    Pfizer noted that the 36 reports does not necessarily mean 36 separate and individual patients got thrombocytopenia after getting the vaccine, citing the possibility of duplicate entries submitted to the VAERS system.


    Representatives for Moderna, the Food and Drug Administration and the CDC did not immediately return FOX News' requests for comment.

  • Calif. man tests positive for COVID-19 weeks after receiving 2nd vaccine dose


    https://news.google.com/articl…=en-US&gl=US&ceid=US%3Aen


    A California man contracted COVID-19 after receiving both doses of the Pfizer vaccine. Health experts warn this could become more common due to the virus variants that have emerged.


    Gary Michael was tested Saturday for COVID-19 when he went to Mission Hospital in Mission Viejo, California, for an unrelated health issue. He later received a phone call from county health officials telling him he tested positive.


    “They told me that, yes, I’m positive with coronavirus, and they went through my symptoms and the precautions of what I should do as far as quarantine,” Michael said.


    With the ongoing pandemic, none of this would be out of the ordinary except for the fact that Michael has received both doses of his COVID-19 vaccine. His first Pfizer shot was Dec. 28, followed by a second one Jan. 18.


    Michael says his case is relatively minor. His live-in girlfriend tested positive for COVID-19 five days after he received his second dose of the vaccine.


    Dr. Tirso del Junco, the chief medical officer for seven Southern California hospitals, says he’s not surprised by Michael’s story.


    “I think I’ve heard of six or seven independent cases over the last three weeks of individuals that have been vaccinated with different timelines that have tested positive, and I think we’re going to continue to see that more and more,” del Junco said.

  • Eli Lilly’s COVID antibody drug combination gets US nod

    Two-drug combination aims to help patients with mild COVID symptoms from becoming more severe


    https://www.aljazeera.com/amp/…g-combination-gets-us-nod






    10 Feb 2021

    Eli Lilly & Co.’s combination antibody drug for Covid-19 was cleared for emergency use by U.S. regulators, providing doctors with a treatment option that is expected to be better able to combat new coronavirus mutations.


    The Food and Drug Administration authorized the treatment for use in Covid-positive adults and children 12 and older who are at high risk of developing severe forms of the disease or progressing to the hospital, according to a fact sheet posted Tuesday by the agency.



    The combo treatment is the second antibody therapy from the Indianapolis-based drugmaker to gain an emergency authorization from the FDA. In November, the agency cleared bamlanivimab, one of the two antibodies used in the cocktail, for use in non-hospitalized, high-risk patients with mild-to-moderate symptoms of Covid-19.


    Bamlanivimab, developed with AbCellera Biologics Inc., mimics the immune system’s virus-fighting powers. Regeneron Pharmaceuticals Inc. also gained FDA authorization for a product combining two antibodies last year. Former President Donald Trump received Regeneron’s drug after contracting Covid-19.


    Many drugmakers, from AstraZeneca Plc to Bristol Myers Squibb Co., are developing products to compete in the increasingly crowded field.



    Lilly’s newly authorized combination includes a 700 milligram dose of bamlanivimab, and a 1,400 milligram dose of another antibody called etesevimab. The tandem will be supplied in separate single-dose vials, but administered together using a single infusion bag, according to the FDA. Patients must get the infusion as soon as possible after a positive Covid-19 test or within 10 days of symptom onset.


    With additional manufacturing help from Amgen Inc., Lilly said it will produce up to 1 million doses of etesevimab for administration with bamlanivimab by mid-2021. The companies have already made 100,000 doses of etesevimab, and another 150,000 doses will be made available throughout the first quarter.


    Underlying Data

    In late January, Lilly reported results from a late-stage trial showing that a combination of bamlanivimab and etesevimab cut the chances of hospitalizations and deaths by 70% in high-risk patients.


    Lilly’s study of the cocktail found no difference between the monotherapy and combination in such outcomes.

  • UK, South African, Brazilian: a virologist explains each COVID variant and what they mean for the pandemic


    The ‘UK variant’ — B.1.1.7

    This variant was first detected in the United Kingdom towards the end of 2020. It has a large number of mutations, many of which involve the virus’ spike protein, which helps the virus invade human cells.


    It has spread rapidly throughout the UK since it emerged, and to at least 70 other countries, including Australia.


    The fact it has spread so rapidly, and quickly replaced other circulating variants, suggests it has some sort of selective advantage over other variants.


    After examining the evidence surrounding the new variant, the UK New and Emerging Respiratory Virus Threats Advisory Group (NERVTAG) concluded it “had moderate confidence” the variant is substantially more infectious than other variants.

    This may be the result of one of the mutations in the spike protein of the variant — a mutation called “N501Y”. One preprint manuscript, uploaded last month and yet to be peer reviewed, found N501Y is associated with increased binding of the virus to a receptor found on the surface on many of our cells, called “ACE2”. This could mean the variant is even more efficient at entering our cells.


    Although initially the variant wasn’t associated with more severe COVID symptoms, more recent data have led NERVTAG to conclude there’s “a realistic possibility” that infection with the variant “is associated with an increased risk of death” compared with non B.1.1.7 viruses.


    However, the group acknowledged there are limitations of the available data, and this remains an evolving situation.


    The ‘South African variant’ — B.1.351

    This variant was first detected in Nelson Mandela Bay, South Africa, in October 2020. Since then it has been found in more than 30 countries.


    Similar to the UK variant, it quickly outcompeted other SARS-CoV-2 variants in South Africa. It now accounts for more than 90% of SARS-CoV-2 samples in South Africa that undergo genetic sequencing.


    Like the UK variant, it also has the N501Y mutation in the spike protein, meaning it’s more efficient at gaining access to our cells to replicate. This may help to explain its rapid spread.


    It also contains several other concerning mutations. Two of these, called “E484K” and “K417N”, are bad news for our immune system. They can reduce how well our antibodies bind to the virus (though this is also based on preprint data awaiting peer review).


    But there’s no evidence yet to suggest the South African variant is more deadly than the original variants.


    The ‘South African variant’ — B.1.351

    This variant was first detected in Nelson Mandela Bay, South Africa, in October 2020. Since then it has been found in more than 30 countries.


    Similar to the UK variant, it quickly outcompeted other SARS-CoV-2 variants in South Africa. It now accounts for more than 90% of SARS-CoV-2 samples in South Africa that undergo genetic sequencing.


    Like the UK variant, it also has the N501Y mutation in the spike protein, meaning it’s more efficient at gaining access to our cells to replicate. This may help to explain its rapid spread.


    It also contains several other concerning mutations. Two of these, called “E484K” and “K417N”, are bad news for our immune system. They can reduce how well our antibodies bind to the virus (though this is also based on preprint data awaiting peer review).


    But there’s no evidence yet to suggest the South African variant is more deadly than the original variants.


    The ‘Brazilian variant’ — P.1

    This variant was first detected in Japan in a group of Brazilian travellers in January 2021.


    It’s now highly prevalent in the Brazilian state of Amazonas, and has been detected in countries including South Korea and the United States.

    Like the South African variant, the Brazilian variant has the spike protein mutations N501Y, E484K and K417N (as well as numerous other mutations).


    While there’s no evidence this variant causes more severe disease, there’s concern it has facilitated a wave of reinfections in Manaus, the largest city in Amazonas, which was thought to have reached “herd immunity” in October last year.


    What does this mean for vaccines?

    Major vaccine developers are testing the efficacy of their vaccines against these and other variants. Generally, the currently licensed vaccines protect relatively well against the UK variant.


    But recent phase 2/3 data from both Novavax and Johnson & Johnson suggest reduced protection against the South African variant. The Oxford/AstraZeneca vaccine group also released data over the weekend suggesting its vaccine offers only minimal protection against mild-moderate disease caused by this variant.


    However, it’s important to recognise reduced protection doesn’t mean no protection at all, and that data are still emerging.


    What’s more, numerous vaccine manufacturers are now investigating whether tweaks to the vaccines can improve their performance against the emerging variants.


    The take-home message is that variants will emerge, and we need to closely monitor their spread. However, there’s every indication we’ll be able to adapt our vaccine strategies to protect against these and future variants.

  • We did the worst job in the world”: Lawrence Wright on America’s botched Covid-19 response

    The three moments that doomed the US effort to combat the coronavirus.




    The story of America’s failure is long and complicated. When the full history is finally written, the depth of those failures will likely shock even those of us who have followed it closely in real time.


    For now, the closest thing we have to a comprehensive account of America’s botched response to the coronavirus is Lawrence Wright’s sweeping story in the New Yorker. Published in December, just a few days before the year ended, the story documents what happened and when, and who was responsible — a staggering piece of reporting that goes as deep as anything written thus far.


    Wright highlights three moments at which America could’ve have gotten things right but, for various reasons, didn’t. It’s as depressing as it is illuminating. I reached out to Wright, who also wrote The End of October, a 2020 novel about a pandemic originating in Asia (seriously), to talk about those three pivotal moments.

    Beyond diagnosing what went wrong, I asked Wright what the federal government could have done differently and if he thinks a competent administration with a serious plan might’ve saved hundreds of thousands of lives. He explained what happened in exquisite detail, and I have to say, it’s maddening. This was indeed a tragedy and, as Wright suggests, one of the greatest failures in the history of American governance.


    A lightly edited transcript of our conversation follows.


    Sean Illing

    You say there are three moments in which America’s Covid-19 response might have gone in a very different direction. Walk me through the first moment, in which China basically attempts to hide the scale of the pandemic in those early days.


    Lawrence Wright

    Right, the first moment occurs when Robert Redfield, the director of the Centers for Disease Control and Prevention, spoke to George Fu Gao, the head of the Chinese Center for Disease Control and Prevention, on January 3, 2020. This was already a fraught moment. Gao had really just started to discover the scale of the thing, and part of the dilemma was that in China people are afraid to report things up the chain. He was basically reading about what was happening on social media.

    The tragic part about this moment is that Gao could not invite the American CDC team to come to China and help investigate the outbreak, and that set us back enormously. Redfield is sure that, had the CDC team been able to visit China at that point, we would’ve discovered that there was asymptomatic transmission, something we didn’t know at that point. This was already something that was being talked about in medical circles in China. It wouldn’t have been a secret. But the US, and really the rest of the world, did not figure this out until late February or early March. And had they known that, the strategy for dealing with this outbreak would have been entirely different.

    Sean Illing

    Did you get any good answers as to why we sat back? It can’t be as simple as naiveté, can it? Or was the US government just scared to death of antagonizing China?


    Lawrence Wright

    All of those things were at play. There was absolutely a fear of antagonizing China. A great example of that is that we wanted to get our diplomats and businesspeople out of Wuhan, and China threw a fit. There was a “How dare you!” quality to their reaction. And in order to placate the Chinese, we sent these 747s over that we were going to use to pick up our citizens, and we stuffed it full of PPE gear, something like 18 tons of it. And we did it purely to mollify the Chinese.

    Sean Illing

    Tell me about the second moment.


    Lawrence Wright

    The second one was the fumble on the testing. The fault lies principally with CDC. But also, the FDA plays a role in this tragedy. The CDC was always the gold standard for public health agencies around the world. And one of the things they do is, they create tests for diseases. And they’ve been very good at that in the past. And of course, they were under terrific pressure in this moment and that in turn led to them taking some shortcuts.


    So there are typically two main elements in a normal test kit, or two parts to the test. One is the primers and probes, as they call them, which detect the presence of viral antibodies. And the other is a piece of RNA that represents the virus. And these two things go together to make a test kit. Normally, you have them manufactured in separate facilities because it contaminates if you have them both in the same house. So the CDC took a shortcut. And they sent out the test kits knowing that it failed their own internal quality check. The fail rate was around 30 percent. But they sent out the kits anyway and they were totally unreliable.

    Sean Illing

    Wait, how the hell does that happen?


    Lawrence Wright

    The CDC didn’t know if it was a design problem or a manufacturing problem. They couldn’t figure it out. So the FDA sent this guy, Timothy Stenzel, down to Atlanta, the CDC headquarters. And it was immediately apparent what had happened. The lab was contaminated. They were processing samples of the test in the same room where they were making the test. So live virus samples were in the same room. And a mistake like that, you just can’t imagine the Centers for Disease Control doing that.


    But there was another thing going on. There were three elements in the primers and probes, numbered one, two, and three. Numbers one and two detected against the SARS-CoV-2 and number three detected any coronavirus, in case it mutated. That was the element that failed. The test worked, except for that third element. All they had to do was to eliminate that third element and you would have a valid test. And the FDA refused to bend on this authorization, for weeks. We lost all of February because of the incompetence and inertia on the part of the CDC and FDA.


    Sean Illing

    You say we “lost all of February,” but what does that mean exactly? Can we even begin to speculate how many lives this dithering and incompetence cost?

    Lawrence Wright

    Well, there are models that show, at every step along the way, had the Chinese been more forthcoming earlier, had the Chinese shut down Wuhan earlier, had we gotten the test out sooner, it would have made an enormous difference in terms of the spread of the virus and the number of lives lost. We can’t say for sure, but had these things gone differently, we would be dealing with a fraction of what we’re facing now.


    “MORE RESPONSIBLE LEADERSHIP COULD HAVE MADE AN IMMENSE DIFFERENCE IN THE SUFFERING AND THE DEATH THAT AMERICA HAS ENDURED”

    Sean Illing

    Did anyone at the CDC or the FDA explain to you why in the world they sent out test kits knowing they were faulty?


    Lawrence Wright

    I asked Redfield about it and he said someone violated protocol. And that’s about it. They have an internal examination. No one’s really been held accountable. No one’s been fired. No one’s been fingered. But it’s pretty clear that it happened in the lab of Stephen Lindstrom, who was overseeing the test. And so far, there’s been no accountability for the failure in CDC.

    I have to say that there’s been no real accountability at the FDA either. Because the FDA could have been responsive to the fact that the test obviously worked if you removed this third element. And they eventually did get it right, but they could have done it weeks earlier and, as I said, the consequences of this delay were enormous.


    Sean Illing

    There’s a crucial moment, on January 23, when a physician (Dr. Rick Bright) from HHS (Health and Human Services) tells various Trump officials, including Secretary Alex Azar, that the “virus might already be here,” and you write that the Trump people “seemed determined to ignore” the news. Does that mean they literally ignored it or does it mean they kept searching for “experts” to tell them what they wanted to hear?


    Lawrence Wright

    Both of those things were going on. They didn’t want to hear the news. They didn’t want to hear any bad news. But also there was this longing for someone to come along and say, “This is not a problem. It’s going away. And if you do nothing, we’ll be fine.” And Scott Atlas served that purpose.

    Sean Illing

    Wait, who is Scott Atlas?


    Lawrence Wright

    Scott Atlas is a neuroradiologist from Stanford who had been on Fox News a lot, saying that we needed to open up the schools, which is a legitimate debate. But he was advocating for “herd immunity,” which is this idea that when enough people have been either vaccinated or infected, the population at large is no longer susceptible to the spread of the disease. The main concept of herd immunity is, let people get sick. We don’t have the vaccine yet. If people get sick, then that will begin to choke off the spread.


    The great appeal for the Trump administration was that you can achieve herd immunity by doing nothing. And that became the unspoken policy.


    Story continues.........https://news.google.com/articles/CAIiEK7SHjYP49DrCu4TFBrwijoqFwgEKg8IACoHCAowlOzSATCaiDUwo9dy?hl=en-US&gl=US&ceid=US%3Aen

  • Dementia Patients Have Twice the Risk of COVID-19

    — African Americans with dementia have even higher risks, especially for hospitalization


    https://www.medpagetoday.com/neurology/dementia/91108


    Dementia patients had a significantly increased risk for COVID-19 and that risk was even higher for African Americans with dementia, a retrospective analysis of U.S. electronic health record (EHR) data showed.


    After adjusting for age, sex, race, and COVID-19 risk factors including comorbidities and nursing home stay, people with dementia had twice the risk of developing COVID-19 as other adults (adjusted OR 2.00, 95% CI 1.94-2.06, P<0.001), according to Rong Xu, PhD, of Case Western Reserve University School of Medicine in Cleveland, and co-authors.

    Among people with dementia, African-American patients were nearly three times as likely to be infected with SARS-CoV-2 as white patients (adjusted OR 2.86, 95% CI 2.67-3.06, P<0.001), they reported in Alzheimer's & Dementia.


    The 6-month mortality risk for patients with dementia and COVID-19 was 20.99%. Hospitalization risk was 59.26%.


    "We have identified patients with dementia as a group that is especially vulnerable to becoming infected with SARS-CoV2," said co-author Pamela Davis, MD, PhD, also of Case Western Reserve University. "Once infected, these patients are especially vulnerable to severe disease and death from COVID."


    "Both of these vulnerabilities occur over and above concomitant known risk factors for COVID, such as nursing-home living, advanced age, hypertension, and diabetes," Davis told MedPage Today. "Physicians should be attuned to this increased risk and take whatever additional measures they can to protect this vulnerable population, such as vaccination, masking, and careful attention to masking and social distancing of caregivers."

  • Vitamin D deficiency as a risk factor for dementia and Alzheimer’s disease: an updated meta-analysis


    https://bmcneurol.biomedcentra…10.1186/s12883-019-1500-6


    Results

    Twelve prospective cohort studies and four cross-sectional studies were included in this meta-analysis. The pooled HRs of dementia and AD, respectively, were 1.32 (95%CI: 1.16, 1.52) and 1.34 (95%CI: 1.13, 1.60) for vitamin D deficiency (< 20 ng/ml). In the subgroup analyses, the pooled HRs of dementia and AD, respectively, were 1.48 (95%CI: 1.19, 1.85) and 1.51 (95%CI: 1.04, 2.18) for moderate vitamin D deficiency (10–20 ng/ml) and 1.20 (95%CI: 0.99, 1.44) and 1.36 (95%CI: 1.01, 1.84) for severe vitamin D deficiency (< 10 ng/ml).


    Conclusion

    There are significant associations between vitamin D deficiency and both dementia and AD. There are stronger associations between severe vitamin D deficiency (< 10 ng/ml) and both dementia and AD compared to moderate vitamin D deficiency (10–20 ng/ml).



    Vitamin D... Vitamin D...... Vitamin D.......VITAMIN D !!!

  • Feeling better ‘in 2 hours’: COVID drug for critically ill starts Phase 3 trials

    Experimental Israeli-made drug Allocetra, developed at Jerusalem's Hadassah hospital, being used to treat so-called cytokine storm, whereby immune system attacks body’s own organs


    https://www.haaretz.com/amp/is…evere-illnesses-1.9526904


    Allocetra treats the over-response of the immune system and inflammatory response that is sometimes seen in COVID-19 patients, called a cytokine storm. The phenomenon can cause severe immune system attacks on the body’s own organs, leading to organ failure and sometimes death.


    One recovered patient, 49-year-old building inspector Yair Tayeb, spoke on his release from the hospital three days after getting the drug.

    “I couldn’t breathe, I could barely speak. [I was in] very very serious condition,” Tayeb said. “I went through an experience you can’t put into words.”


    Within two hours of receiving the drug, he said, he felt a change. “They gave me the drug. Suddenly after two hours I started feeling something strange in my body. I stopped coughing, my breathing started to come back, I was feeling better. I stopped sweating. I couldn’t believe it. I was afraid to tell people I was okay, I was so excited.”

    Prof. Dror Mevorach, head of one of Hadassah’s coronavirus wards and chief scientific and medical officer at Enlivex, who developed the treatment, told Channel 13: “It is useful for serious and critical patients because it can prevent the need to ventilate them, and that’s the major goal. Because the moment you go into ventilation, the entire situation changes, complications rise, and it’s more difficult to treat.”


    The drug is now entering Phase 3 trials and will be given to over 100 people.